IRIDEX Corporation revised revenue guidance for the fourth quarter and provided revenue guidance for the full year of 2015. For the quarter, the company expects revenues of approximately $11.9 million to $12.2 million. Preliminary revenues in the fourth quarter exceeded the high end of the company's guidance and were driven by a continued strong uptick in sales of the Cyclo G6™ Glaucoma Laser System on top of the steady, stable growth in the Micropulse® technologies targeting retinal conditions. The company had previously projected revenues to be between $11.5 million and $11.9 million in the fourth quarter of 2015. The sale of Cyclo G6 systems for the year was more than 10% greater than the company's projection of 100 units.

For the year, the company expects revenue of approximately $41.5 million to $41.8 million.